Physician
Haydee Te Nievera, M.D., PA
Haydee Te Nievera, M.D., PA was paid $4.20M by Medicaid between Jan 2020 and Dec 2024, across 62 billing codes. Its largest line is 99213, doctor's office visit, returning patient (routine) — 23% of everything it billed.
33Billing provider infoHAYDEE TE NIEVERA, M.D., PA
BROWNSVILLE, TX 78526
BROWNSVILLE, TX 78526
33aNPI1720101454assigned 04/09/2007
33bProvider typePediatrics Physician
28Total paid$4.20M
24GClaims167,533
24DCodes billed62
24AFirst – last monthJan 2020 – Dec 2024
Compared with peers
Next to other Pediatrics Physician providers in Texas
Rank by total paid#107 of 1,136
Median peer was paid$329K
This provider vs. median13×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 9,159 | $192K | |
| 2021 | 48,459 | $1.14M | |
| 2022 | 54,789 | $1.33M | |
| 2023 | 37,105 | $974K | |
| 2024incomplete | 18,021 | $564K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 23% | 22,612 | 17,867 | $955K |
| S8301 | Infection control supplies, not otherwise specified | 14% | 22,157 | 17,590 | $569K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 8.0% | 7,999 | 7,190 | $337K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 7.8% | 12,528 | 10,441 | $326K |
| 87428 | 5.5% | 3,395 | 3,064 | $232K | |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | 4.9% | 2,489 | 2,435 | $207K |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | 4.6% | 2,480 | 2,434 | $195K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 4.3% | 13,288 | 6,151 | $179K |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.1% | 2,817 | 2,563 | $170K |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | 3.6% | 1,789 | 1,746 | $151K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 3.2% | 10,064 | 9,300 | $136K |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | 3.1% | 12,436 | 6,020 | $130K |
50 more codes
| 99000 | 3.0% | 12,232 | $124K | |
| 99391 | Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) | 2.7% | 1,496 | $115K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 1.7% | 904 | $70K |
| 99429 | 1.5% | 1,980 | $64K | |
| 92552 | 1.5% | 4,666 | $62K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.4% | 1,212 | $59K |
| 96110 | Developmental screening, with scoring and documentation, per standardized instrument | <1% | 2,379 | $19K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 118 | $15K |
| 90461 | <1% | 2,172 | $13K | |
| 99050 | <1% | 710 | $10K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,539 | $10K |
| 92567 | <1% | 762 | $9K | |
| CP002 | <1% | 863 | $8K | |
| 99051 | <1% | 1,476 | $8K | |
| 86328 | <1% | 155 | $6K | |
| 87807 | <1% | 486 | $5K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 277 | $4K |
| 96161 | <1% | 1,691 | $4K | |
| 0071A | <1% | 85 | $3K | |
| 0072A | <1% | 83 | $3K | |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 68 | $3K |
| 81003 | <1% | 1,065 | $2K | |
| 86580 | <1% | 156 | $1K | |
| 90473 | <1% | 40 | $481.25 | |
| 92587 | <1% | 28 | $335.36 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 20 | $195.67 |
| 96160 | <1% | 66 | $2.25 | |
| 90686 | <1% | 2,094 | $0.44 | |
| 90677 | <1% | 237 | $0.35 | |
| 90672 | <1% | 406 | $0.10 | |
| 90651 | <1% | 102 | $0.05 | |
| 90620 | <1% | 94 | $0.02 | |
| 90710 | 0% | 172 | $0.00 | |
| 99173 | 0% | 4,669 | $0.00 | |
| 90670 | 0% | 981 | $0.00 | |
| 90734 | 0% | 125 | $0.00 | |
| 90633 | 0% | 256 | $0.00 | |
| 82735 | 0% | 13 | $0.00 | |
| 2001F | 0% | 1,646 | $0.00 | |
| 36416 | 0% | 1,489 | $0.00 | |
| 90680 | 0% | 464 | $0.00 | |
| 90723 | 0% | 573 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 736 | $0.00 |
| 3008F | 0% | 1,644 | $0.00 | |
| 90647 | 0% | 582 | $0.00 | |
| 91307 | 0% | 192 | $0.00 | |
| 90660 | 0% | 42 | $0.00 | |
| 90656 | 0% | 209 | $0.00 | |
| 90696 | 0% | 12 | $0.00 | |
| D1208 | Topical application of fluoride, excluding varnish | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialNIEVERA, HAYDEE (PRESIDENT)